GlobeNewswire by notified

Nexstim Receives an NBS System Order from a Customer in Europe

Share

Nexstim Receives an NBS System Order from a Customer in Europe

Press release, Helsinki, 25August 2022 at 10AM (EET)

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received an NBS 5 System order from a customer in Europe. The customer is a new user of the Nexstim NBS system, acquiring the system to enable future neuroscience projects.

Nexstim’s SmartFocus® nTMS (navigated transcranial magnetic stimulation) technology enables accurate and personalized stimulation, considering the unique shape and conductivity of each patient’s brain. Nexstim’s NBS (Navigated Brain Stimulation) system is used, for example, in planning neurosurgery and in the case of this customer enables neuroscience studies where the stimulation needs to be targeted individually to the brain, reproducing the pulse delivery reliably for diagnosis.

This specific NBS system also includes the software of an NBT® (Navigated Brain Therapy) system, allowing it to also be used for the treatment of major depression and chronic neuropathic pain.

Mikko Karvinen, CEO of Nexstim, comments: Nexstim has been actively working as a partner in TMS-EEG development. TMS-evoked EEG responses are sensitive to even the smallest shifts in stimulation location. While allowing highly location-specific data to be gathered, this also makes a reliable, precise and accurate navigation solution imperative for TMS-EEG measurements and even more so when studies require repeatability and reproducibility.We are very happy to see that our development work at Nexstim results in enabling new customers to use our world-leading technology in their neuroscience research projects.

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit www.nexstim.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

MT Højgaard Holding A/S: MT Højgaard Danmark to construct production facility for Novo Nordisk2.12.2022 11:27:08 CET | Press release

MT Højgaard Holding’s business unit MT Højgaard Danmark has entered a cooperation-based contract with Novo Nordisk for the construction of a production facility as well as modification and extension of existing buildings in Bagsværd. The project is executed in cooperation with Kemp & Lauritzen, and the total contract sum is estimated at DKK 1.2 billion of which MT Højgaard Danmark’s estimated share constitutes DKK 600 million. The project has been initiated immediately and is expected to be completed in the second half of 2024. The contract does not change MT Højgaard Holding’s previously announced 2022 outlook, but it will contribute significantly to the group’s long-term, sustainable development in the coming years. Contact: CEO Henrik Mielke and CFO Martin Solberg can be contacted on telephone +45 22 70 93 65. Attachment MTHH_Company announcement 2Dec22

MT Højgaard Holding A/S: MT Højgaard Danmark skal udføre produktionsbygning for Novo Nordisk2.12.2022 11:27:08 CET | pressemeddelelse

MT Højgaard Holdings forretningsenhed MT Højgaard Danmark har indgået en samarbejdsbaseret kontrakt med Novo Nordisk om opførelse af en produktionsbygning samt om- og tilbygning af eksisterende bygninger i Bagsværd. Opgaven udføres i samarbejde med Kemp & Lauritzen, og den samlede kontraktsum er estimeret til at udgøre 1,2 mia. kr., hvoraf MT Højgaard Danmarks andel er estimeret til at udgøre 600 mio. kr. Projektet er iværksat straks og forventes fuldført i 2. halvår 2024. Kontrakten ændrer ikke MT Højgaard Holdings udmeldte forventninger til 2022, men vil yde et væsentligt bidrag til koncernens langsigtede, bæredygtige udvikling i de kommende år. Yderligere oplysninger: Henvendelse til koncernchef Henrik Mielke og CFO Martin Solberg kan ske på telefon +45 22 70 93 65. Vedhæftet fil MTHH_Selskabsmeddelelse 2dec22

Colliers completes acquisition of Pangea2.12.2022 10:00:40 CET | Press release

TORONTO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Leading diversified professional services and investment management firm Colliers (NASDAQ and TSX: CIGI) has completed its previously announced acquisition of a controlling interest in Pangea Property Partners (“Pangea”), a leading capital markets advisor in Sweden and Norway. Pangea becomes Colliers’ new company-owned operation in Norway and will merge with Colliers’ existing company-owned operations in Sweden. This transaction firmly positions Colliers as the dominant player in the Nordic region, building on our top-tier operations in Denmark and Finland. About Colliers Colliers (NASDAQ, TSX: CIGI) is a leading diversified professional services and investment management company. With operations in 63 countries, our 18,000 enterprising professionals work collaboratively to provide expert real estate and investment advice to clients. For more than 27 years, our experienced leadership with significant inside ownership has delivered compound ann